Assessing the safety and effectiveness of ABBV-932 for anxiety treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of ABBV-932, an investigational drug, when added to existing antidepressant therapies in adults with generalized anxiety disorder (GAD) who have not responded adequately to their current treatment. Participants will be randomly assigned to receive either ABBV-932 or a placebo alongside their prescribed antidepressants for a duration of 6 weeks, followed by a 4-week follow-up period. The study aims to enroll approximately 315 participants across 50 sites in the United States and Puerto Rico.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).
* Currently taking protocol-specified antidepressant therapies (ADT) for GAD with an inadequate response to an adequate dose (per label) and duration (\>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score \>= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) \>= 4.

Exclusion Criteria:

* Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score \>= 20.
* New diagnosis or exacerbation of major depression in the last 6 months.

Where it's running

• University of Alabama - Huntsville Regional Medical Campus /ID# 267818
  Huntsville, Alabama, United States Recruiting
• Ima Clinical Research Phoenix (Alea) /ID# 275737
  Phoenix, Arizona, United States Recruiting
• Advanced Research Center /ID# 267874
  Anaheim, California, United States Recruiting
• Axiom Research /ID# 267814
  Colton, California, United States Recruiting
• Sun Valley Research Center /ID# 267864
  Imperial, California, United States Recruiting
• Synergy San Diego /ID# 267879
  Lemon Grove, California, United States Recruiting

+2 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Breathing and exercise to help Generalized Anxiety Disorder

  This study tests whether adding inspiratory muscle training or diaphragmatic breathing to a combined exercise program can help reduce anxiety symptoms in adults with GAD, compared with a breathing-based control using progressive muscle relaxation.

  Recruiting Saglik Bilimleri Universitesi · Istanbul, Uskudar · NCT07913503

• Device-based brain stimulation to help Generalized Anxiety Disorder

  A non-invasive brain-stimulation device is tested to see if it can reduce anxiety symptoms in adults with Generalized Anxiety Disorder.

  Recruiting at 3 sites BTL Industries Ltd. · Denver, Colorado and 2 other locations · NCT07819773

• Solution-Focused Therapy for Generalized Anxiety Disorder in emerging adults

  This study tests whether Solution-Focused Therapy can reduce worry and anxiety in 18-29 year-olds with mild to moderate GAD in Pakistan.

  Recruiting International Islamic University, Islamabad · Islamabad · NCT07798063

• CIDI 5.0 validation against SCID-5 for lifetime mental disorders in Hong Kong adults

  This study tests whether the CIDI 5.0 interview can reliably identify lifetime mental disorders in adults in Hong Kong by comparing it with the SCID-5 diagnostic interview.

  Recruiting The University of Hong Kong · Hong Kong · NCT07604753

• Personalized AI-driven robot companions to support CBT for anxiety in college students

  This test tries whether personalized AI-driven robot companions can help college students with anxiety stick to CBT exercises and reduce symptoms.

  Recruiting University of Southern California · Los Angeles, California · NCT07430800

• Transcranial alternating current stimulation for generalized anxiety disorder and chronic insomnia

  This study will try 20 sessions of transcranial alternating current stimulation (tACS) with the Nexalin device to see if it improves anxiety and sleep in adults with generalized anxiety disorder and chronic insomnia.

  Recruiting University of Sao Paulo · São Paulo, São Paulo · NCT07429578

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.